N-(2-Methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine (CAS 152460-09-8)

Application and positioning

The pyrimidin-2-amine intermediate on the imatinib route — the nitro group is reduced in the next step to reach the imatinib core. Catalyst-poisoning impurities kept low because the following hydrogenation is the customer's step; ≥99% HPLC. Laurand supplies it from audited Chinese producers in kilogram to multi-hundred-kilogram lots; process and regulatory documentation is coordinated case by case with the manufacturing site.

Quality and documentation

• Batch-specific Certificate of Analysis with HPLC purity and a full impurity profile
• Chiral purity by chiral HPLC where the molecule carries defined stereocentres
• Residual solvent data against ICH Q3C and elemental impurity data against ICH Q3D on request
• Structure confirmation by NMR and MS on first shipments
• SDS in the language of your market, with GHS classification for the destination

Packaging and handling

• 1 kg, 5 kg and 25 kg fibre drums with inner PE liner; amber glass bottles for gram quantities
• Sealed, dry and protected from light; cold-chain arrangement discussed per product where the intermediate requires it
• Store at ambient temperature in a dry warehouse, away from oxidising agents and moisture

Related products

• 4-Chloro-7-methoxyquinoline-6-carboxamide (CAS 417721-36-9)
• 2-Amino-6-chloropurine (CAS 10310-21-1)
• 7-Aminocephalosporanic acid (CAS 957-68-6)
• 6-Aminopenicillanic acid (CAS 551-16-6)

Values marked (predicted) are calculated estimates; the rest are published literature or supplier data. Where a property has no published value we leave it blank rather than estimate it. The specification of the delivered lot is confirmed with the quotation.